Last reviewed · How we verify

NCT03615859: OMNI-AID

Objective Markers and New Indicators in AI Disease (OMNI-AID Study)

Status unknown Last updated 15 August 2019
What this trial tests

trial in Adrenal Insufficiency in 100 participants. Status unknown.

Timeline
1 June 2018
Primary endpoint
2 April 2021
2 April 2021

Quick facts

Lead sponsorImperial College London
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment100
Start date1 June 2018
Primary completion2 April 2021
Estimated completion2 April 2021
Sites1 location across United Kingdom

Conditions studied

Sponsor

Imperial College London

Who can join

Adults 18 to 85, any sex, with Adrenal Insufficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot study is designed to compare healthy volunteers with three groups of patients with adrenal insufficiency and a final group of patients receiving high dose steroids for anti-inflammatory purposes. The study will collect data on all 5 groups with the intention of identifying any novel markers or immunological indicators which may be used clinically to gauge the adequacy of steroid replacement treatment in patients with adrenal insufficiency.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Adrenal Insufficiency

Currently open trials in the same condition.

Other Imperial College London trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03615859.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing